Systemic lupus erythermatosus (SLE), is a chronic autoimmune disease that can affect almost any organ system; thus, its presentation and course are highly variable, ranging from indolent to fulminant.
Previously, mortality was due to the disease itself; currently, mortality is often a result of medication side effects (i.e., fatal infections in individuals receiving potent immunosuppressive medications) or cardiovascular events.
According to the Centers for Disease Control and Prevention (CDC), however, one third of SLE-related deaths in the United States occur in patients younger than 45 years, making this a serious issue despite declining overall mortality rates. 
Actual Medical Prognosis
Statistician Urowitz first reported a difference in mortality between early versus late diagnosis of SLE in life, noting that SLE-related deaths usually occurred within the first 5-10 years of symptom onset. Mortality in the first few years of illness is typically from severe SLE disease (eg, Central Nervous System, renal, or cardiovascular involvement) or infection related to immunosuppressive treatment. Infections account for 29% of all deaths in these patients. 
Late deaths (after age 35 years) are generally from myocardial infarction or stroke secondary to accelerated atherosclerosis (hardening and obstruction of the arteries) [4, 5, 6, 7]; inflammation –which is central to SLE– plays a major role in the development and accelerated progression of atherosclerosis. Scientists Manzi, et al. reported that women aged 35-44 years with SLE were 50 times more likely to develop greater lack of blood flow in the heart than healthy Framingham study control women. The presence of kidney involvement may further increase these risks. 
World Stem Cells Clinic’s Advanced Stem Cell Therapy (ASCT) for Systemic Lupus Erythematosous
The approach of treating the symptoms exclusively and primarily by utilizing drugs has been the mainstay in medical therapies for lupus for years. With the many new findings in stem cell research the autoimmune components of SLE may be reset or adequately modified to modulate this disorder.
With the patient’s own adult stem cells, previously stimulated and then enhanced and expanded at our laboratory we address some of the underlying causes of the disease. Stem cells induce physical changes in the body to help it effectively regulate its immune response to heal and gain a better quality of life. Our studies have proven our stem cell protocol to be safe, and does not require complete suppression of the immune system.
The modification of the autoimmune dysfunction with stabilization and some reversal of the disease are shown in a number of studies below. [9 – 16]
A study designed and conducted at World Stem Cells Clinic for SLE successfully delivered:
- A significant Increase in overall energy.
- Improvement in body constitution and less weight changes.
- Reduction in fever and infection risks.
- Amelioration of joint pain or deformity.
- Decrease in frequency of flares, skin improvements.
- Better pulmonary and renal function measured in spirometry and GFR.
- Stability of neurologic and psychiatric manifestations of the disease.
- We have frequent reports from our patients about a general betterment of their quality of life.
News and references supporting our studies
 Office of Minority Health & Health Disparities (OMHD). Eliminate Disparities in Lupus. LINK: Available at http://www.cdc.gov/omhd/amh/factsheets/lupus.htm. Accessed March 21, 2012
 Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. Feb 1976;60(2):221-5. LINK: www.ncbi.nlm.nih.gov/pubmed/1251849
 Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). May 1999;78(3):167-75. LINK: www.ncbi.nlm.nih.gov/pubmed/10352648
 Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR. Systemic lupus erythematosus. Lancet. Mar 31 2001;357(9261):1027-32. LINK: www.ncbi.nlm.nih.gov/pubmed/17307106
 Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. Mar 1 1997;145(5):408-15. LINK: www.ncbi.nlm.nih.gov/pubmed/9048514
 Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol. Sep 2001;13(5):345-51. LINK: www.ncbi.nlm.nih.gov/pubmed/11604587
 Gladman DD, Urowitz MB. Prognosis, mortality and morbidity in systemic lupus erythematosus In: Wallace DJ, Hahn BH. Dubois’ lupus erythematosus. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2007:1333-53. LINK: books.google.com.mx/books?isbn=0781793947
 Faurschou M, Mellemkjaer L, Starklint H, et al. High risk of ischemic heart disease in patients with lupus nephritis. J Rheumatol. Nov 2011;38(11):2400-5. LINK: www.ncbi.nlm.nih.gov/pubmed/21885497
 Stem Cell Transplant Benefits Severe Lupus. Reviewed by Zalman S. Agus, MD; Emeritus Professor University of Pennsylvania School of Medicine and Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner. LINK: www.medpagetoday.com/Rheumatology/Lupus/21437
 Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Sun L, Akiyama K, Zhang H, Yamaza T. Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China. LINK: www.ncbi.nlm.nih.gov/pubmed/19489103
 Stem Cell Infusions Reverse Lupus Complications, Songtao Shi, associate professor at the USC School of Dentistry Published on Mar 19, 2009 Stem Cells. LINK: http://news.usc.edu/#!/article/30542/Stem-Cell-Infusions-Reverse-Lupus-Complications
 Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus a pilot clinical study. Jun Liang, Huayong Zhang, Bingzhu Hua, Hong Wang, Liwei Lu, Songtao Shi. In correspondance to Dr Gary S Gilkeson, Department of Rheumatology, 96 Jonathan Lucas Street, Suite 912 Medical University of South Carolina, Charleston, South Carolina. May 2010. LINK: www.ncbi.nlm.nih.gov/pubmed/20650877
 Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Soufiane Ghannam, Carine Bouffi, Farida Djouad, Christian Jorgensen and Danièle Noël. Stem Cell Research & Therapy 2010, 1:2 doi:10.1186/scrt2. 2010 LINK: www.ncbi.nlm.nih.gov/pubmed/20504283
 A big step forward in the treatment of refractory systemic lupus erythematosus: allogenic mesenchymal stem cell transplantation. Shang-xue Yan, Xiao-mei Deng and Wei Wei. Acta Pharmacologica Sinica (2013) 34: 453–454; doi: 10.1038/aps.2013.33 LINK: http://www.nature.com/aps/journal/v34/n4/full/aps201333a.html
 Stem cell transplants offer hope against lupus. Roxanne Khamsi. 21:00 31 January 2006. Journal reference: Journal of the American Medical Association (DOI: 10.1001_JAMA.295.5.527)LINK: http://www.newscientist.com/article/dn8657-stem-cell-transplants-offer-hope-against-lupus.html#.UwuM-_RdXw4
 Safety reporting on implantation of autologous adipose tissue-derived stem cells with platelet-rich plasma into human articular joints. Jaewoo Pak, Jae-Jin Chang, Jung Hun Lee and Sang Hee Lee BMC Musculoskeletal Disorders 2013, 14:337. LINK: www.biomedcentral.com/1471-2474/14/337